What’s next for obesity and weight loss drugs?

Kara L. Marlatt, PhD, MPH spoke with Contemporary OB / GYN® after her presentation to the North American Menopause Society on Treating Weight Gain During Menopause. Marlatt is an assistant research professor at the Pennington Biomedical Research Center at Louisiana State University in Baton Rouge, LA and specializes in aging and healthy metabolism.


  • 2.4 mg weekly subcutaneous injection
  • 15-17% weight loss


VSagrilintide + semaglutide

  • Cagrilintide is an amylin analogue and is associated with semaglutide
  • 20% to 25% weight loss


“There’s also an exciting drug that’s in Phase 2 trials that could be an improvement as well. What these studies show so far is that with weight loss there is actually a Fat loss. But more importantly, there is retention, or there is non-fat mass gain. And so really, I think these new cutting edge drugs will do just that.

So with weight loss you are not going to see 75% fat loss but you will also get 25% fat free mass loss. Instead, it rocks. It’s a game-changer in that now you’re not only going to lose fat, but you could actually gain mass without fat, so it’s really good for aging in general.

These are the ones that are the most exciting to come and that people should be looking for. I think the most important thing is that doctors and practitioners who deal with patients should really be patient, but very optimistic that these drugs will become more readily available. It’s really going to bridge that gap between what lifestyle intervention can do and what weight loss surgery can do. We are really getting closer to what weight loss surgery can do. “

Source link

Comments are closed.